Let's take a look at the stocks that are in motion in today's session.
By Mill Chart
Last update: Mar 26, 2024
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Gainers
| Ticker | Change | Comment |
|---|---|---|
| ETAO | 2.0K% | ETAO INTERNATIONAL CO LTD (NASDAQ:ETAO) rose 2.0K% to $4.89 during Tuesday's after hours session. The stock is trading 37.59% higher than a month ago. |
| MESO | 74.77% | MESOBLAST LTD- SPON ADR's (NASDAQ:MESO) shares rose 74.77% to $3.85. In the last year the share price dropped with 64.4%. |
| STOK | 71.38% | In an impressive move, STOKE THERAPEUTICS INC's (NASDAQ:STOK) shares recorded a 71.38% increase, closing at $11.14 during Tuesday's session. Yesterday the company had a press release: Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results. |
| CZOO | 43.81% | CAZOO GROUP LTD (NYSE:CZOO) rose 43.81% to $5.58 during Tuesday's after hours session. The stock is trading 59.16% lower than 3 months ago. |
| OPGN | 43.58% | OPGEN INC (NASDAQ:OPGN) rose 43.58% to $0.68 during Tuesday's after hours session. The company's earnings where released Yesterday. A press release (OpGen Announces Acquisition of Preferred Stock by David Lazar) was released yesterday. |
| CISS | 37.5% | C3IS INC's (NASDAQ:CISS) stock price is advancing with 37.5% to a price of $0.05. The stock is trading 65.89% lower than a month ago. |
| NUVB | 30.0% | Positive market sentiment drove NUVATION BIO INC's (NYSE:NUVB) stock price up by 30.0% to $2.92 during Tuesday's session. Yesterday the company had a press release: Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction. |
| KULR | 27.81% | KULR TECHNOLOGY GROUP INC (NYSEARCA:KULR) rose 27.81% to $0.42 during Tuesday's after hours session. Earlier today the company had a press release: Global Electronic Warfare Market Size Expected to Reach $24.76 Billion by 2029. |
| DNUT | 27.07% | KRISPY KREME INC's (NASDAQ:DNUT) shares rose 27.07% to $15.82. Earlier today the company had a press release: McDonald’s® USA and Krispy Kreme® Announce Expanded National Partnership. |
| DERM | 27.05% | Investors witnessed a remarkable 27.05% rise in JOURNEY MEDICAL CORP's (NASDAQ:DERM) shares, which climbed to $3.71 during Tuesday's session. Shareholders saw the stock price going 22.55% lower in the past month. |
For the full top gainers list go to our top gainers page.
Losers
| Ticker | Change | Comment |
|---|---|---|
| NBSE | -54.01% | Investors witnessed a 54.01% decrease in NEUBASE THERAPEUTICS INC's (NASDAQ:NBSE) stock price, which closed at $0.46 during Tuesday's session. In the last 3 months the share price increased with 35.12%. |
| EGOX | -31.83% | NEXT.E.GO NV's (NASDAQ:EGOX) shares fell 31.83% to $0.03 during Tuesday's session. In the last month the stock lost 57.41%. |
| CDLX | -30.91% | There was a notable decline in CARDLYTICS INC's (NASDAQ:CDLX) shares, as they dropped 30.91% to $13.99 during Tuesday's session. A press release (Cardlytics Announces Proposed Convertible Senior Notes Offering) was released earlier today. |
| GDS | -24.67% | There was a downturn in GDS HOLDINGS LTD - ADR's (NASDAQ:GDS) shares, as they experienced a 24.67% decline, closing at $6.3 during Tuesday's session. yesterday the company released their earnings. A press release (GDS Appoints Jamie Khoo As CEO of GDS International) was released earlier today. |
| WISA | -21.28% | WISA TECHNOLOGIES INC's (NASDAQ:WISA) shares fell 21.28% to $0.02 during Tuesday's session. A press release (WiSA Technologies Announces Pricing of $2.3 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market) was released earlier today. |
| RBT | -20.77% | RUBICON TECHNOLOGIES INC (NYSE:RBT) encountered a 20.77% decrease in its shares, reaching $0.34 during Tuesday's session. Yesterday the company had a press release: Rubicon Launches Technical Advisory Services (TAS) Offering. |
| NCNC | -20.74% | NOCO-NOCO INC's (NASDAQ:NCNC) shares fell 20.74% to $0.26. In the last month the share price increased with 75.95%. |
| EQ | -19.47% | There was a downturn in EQUILLIUM INC's (NASDAQ:EQ) shares, as they experienced a 19.47% decline, closing at $1.97 during Tuesday's session. Yesterday the company had a press release: Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights. |
| BCAN | -18.37% | There was a notable decline in BYND CANNASOFT ENTERPRISES's (NASDAQ:BCAN) shares, as they dropped 18.37% to $1.6 during Tuesday's session. In the last month the share price dropped with 94.41%. |
| BDRX | -18.1% | BIODEXA PHARMACEUTICALS-ADR's (NASDAQ:BDRX) shares fell 18.1% to $0.8. In the last month the share price dropped with 29.5%. |
To see the full list of top losers you can use our top losers page.
JOURNEY MEDICAL CORP
NASDAQ:DERM (4/26/2024, 7:00:00 PM)
3.4
-0.1 (-2.86%)
DERM News
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...
18 days ago - InvestorPlace3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
a month ago - InvestorPlaceDERM Stock Earnings: Journey Medical Beats EPS, Beats Revenue for Q4 2023DERM stock results show that Journey Medical beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
a month ago - BusinessInsiderDERM Stock Earnings: Journey Medical Beats EPS, Beats Revenue for Q4 2023InvestorPlace - Stock Market News, Stock Advice & Trading Tips Journey Medical (NASDAQ:DERM) just reported results for the fourth quarter of 2...
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 ...
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024...
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET...
SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical...
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that...
4 months ago - Seeking AlphaJourney Medical submits NDA for DFD-29 for rosacea (NASDAQ:DERM)Journey Medical (FBIO) said it has submitted a New Drug Application for its rosacea treatment DFD-29. The product is being developed with Dr. Reddy's (RDY). Read more here.
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea...
4 months ago - Seeking AlphaJourney Medical secures credit facility for up to $20M (NASDAQ:DERM)Journey Medical secures credit facility with SWK Holdings, allowing for borrowings of up to $20M to fund corporate operations and product development.
